Seres Therapeutics gets FDA priority review designation for SER-109 in rCDI
Seres Therapeutics has secured priority review designation from the US Food and Drug Administration (FDA) for SER-109, its investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). The biologics license application (BLA) of the American microbiome therapeutics company for SER-109 has been given a prescription drug user fee act (PDUFA) action […]